Christina Shafer - Jun 15, 2022 Form 3 Insider Report for MARINUS PHARMACEUTICALS, INC. (MRNS)

Role
Chief Commercial Officer
Signature
/s/Debra A. Mohollen, Attorney-in-Fact
Stock symbol
MRNS
Transactions as of
Jun 15, 2022
Transactions value $
$0
Form type
3
Date filed
6/23/2022, 04:05 PM
Next filing
Nov 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRNS Common Stock 27.2K Jun 15, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MRNS Stock Option (Right to Buy) Jun 15, 2022 Common Stock 128K $13.71 Direct F2
holding MRNS Stock Option (Right to Buy) Jun 15, 2022 Common Stock 15K $12.60 Direct F3
holding MRNS Stock Option (Right to Buy) Jun 15, 2022 Common Stock 57.9K $10.40 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes: (i) 10,000 shares of restricted stock granted on November 9, 2020, of which 5,000 vested on November 9, 2021 and 1,505 of those shares were withheld to cover taxes, and the remaining 5,000 RSAs will vest on November 9, 2022, subject to the reporting person's continued service with the Issuer, (ii) 12,867 restricted stock units (RSUs) granted on February 4, 2022 that vest in three equal installments, with the first installment vesting on August 4, 2023, the second installment vesting on August 4, 2024, and the third installment vesting on August 4, 2024, subject to the reporting person's continued service with the Issuer, and (iii) 5,790 RSUs granted on May 24, 2022 that vest in two equal installments with the first installment vesting on August 4, 2023, and the second installment vesting on August 4, 2024, subject to the reporting person's continued service with the Issuer. Each RSU represents the right to receive one share of common stock of the Issuer.
F2 An option to purchase 128,000 shares of common stock of the Issuer was granted on November 9, 2020, of which 25%, or 32,000 shares, vested and became exercisable on November 9, 2021 and the remaining shares underlying the option began vesting in 36 equal monthly installments on December 9, 2021.
F3 An option to purchase 15,000 shares of common stock of the Issuer was granted on January 15, 2021. The shares underlying the option began vesting in 36 equal monthly installments on January 31, 2021.
F4 An option to purchase 57,900 shares of common stock of the Issuer was granted on February 4, 2022. The shares underlying the option began vesting in 36 equal monthly installments on March 4, 2022.

Remarks:

Exhibit 24- Power of Attorney